Merck
CN
  • Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Journal of clinical epidemiology (2013-07-17)
Jason T Connor, Jordan J Elm, Kristine R Broglio
摘要

We present a novel Bayesian adaptive comparative effectiveness trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping. The trial will enroll 720 unique patients in emergency departments and uses a Bayesian adaptive design. The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment. When one treatment is superior to the other two, the trial design provides better patient care, higher power, and a lower expected sample size.

材料
货号
品牌
产品描述

Supelco
丙戊酸, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
苯妥英钠, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5,5-二苯基海因, ≥98%
Sigma-Aldrich
2-丙基戊酸
Supelco
丙戊酸标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
吡拉西坦
Supelco
苯妥英标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
苯妥英钠, European Pharmacopoeia (EP) Reference Standard
苯妥英钠, European Pharmacopoeia (EP) Reference Standard
左乙拉西坦, European Pharmacopoeia (EP) Reference Standard
Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard